John R Kao, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · Apex Cardiology of Silicon Valley A Medical Partnership · 3 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kao’s office at (408) 369-7500 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$786,261
Medicare paid this office $786,261 for 737 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 163 | $157,397 | $948 |
| Injection, inclisiran, 1 mg | 23 | $108,449 | None |
| Return visit (30+ min) | 500 | $90,466 | $119 |
| Long return visit (40+ min) | 245 | $61,186 | $169 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 282 | $57,522 | $198 |
See all 37 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 163 | $157,397 | $948 |
| Injection, inclisiran, 1 mg | 23 | $108,449 | None |
| Return visit (30+ min) | 500 | $90,466 | $119 |
| Long return visit (40+ min) | 245 | $61,186 | $169 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 282 | $57,522 | $198 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 94 | $45,397 | $483 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $20,796 | $111 |
| New patient visit (60+ min) | 104 | $19,935 | $192 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 20 | $19,797 | $112 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 82 | $19,507 | $238 |
| Critical care, first 30-74 minutes | 36 | $17,346 | $195 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 29 | $15,022 | $64 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 94 | $14,739 | $78 |
| Ultrasound of both sides of head and neck blood flow | 54 | $10,297 | $191 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 50 | $9,098 | $162 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 109 | $7,533 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 350 | $6,100 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 78 | $5,940 | $64 |
| New patient visit (45+ min) | 33 | $5,189 | $157 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 260 | $4,453 | $14 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 21 | $3,969 | $173 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 161 | $3,912 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 48 | $3,784 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 45 | $3,730 | $27 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 11 | $3,582 | $326 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 26 | $2,143 | $82 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 63 | $1,684 | $21 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 82 | $1,456 | $6 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 13 | $1,394 | $82 |
| Injection, regadenoson, 0.1 mg | 56 | $1,354 | None |
| Programming of dual lead pacemaker system | 11 | $1,198 | $80 |
| Anticoagulant management of patient taking warfarin | 14 | $1,043 | $10 |
| Nuclear medicine study of heart muscle blood flow by pet | 26 | $705 | $27 |
| Injection of drug or substance under skin or into muscle | 23 | $514 | $15 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 36 | $495 | $11 |
| Ultrasonic guidance for blood vessel access | 35 | $475 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 26 | $341 | $13 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 14 | More than 36% of doctors who do this |
Who their Medicare patients are
737 Original Medicare patients in 2024. Average age 78 · Women 46% · Also on Medicaid 6% · Health risk score 1.39. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 52% · Atrial fibrillation 40% · Diabetes 34% · Heart failure 28% · Chronic kidney disease 28% · Cancer 18% · Stroke 14% · COPD 12% · Depression 12% · Dementia 8%.
The office billed $1,718,615, Medicare allowed $1,012,414 and paid $786,261; for 16,724 services of 85 kinds; $109,803 of it was for drugs given in the office and $676,458 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 737 | 16,724 | 78 | 1.39 | $1,718,615 | $786,261 |
| 2023 | 778 | 5,711 | 79 | 1.32 | $1,636,170 | $689,998 |
| 2022 | 789 | 5,670 | 79 | 1.43 | $1,631,940 | $695,499 |
| 2021 | 712 | 5,762 | 79 | 1.33 | $1,812,560 | $755,857 |
| 2020 | 684 | 5,072 | 79 | 1.38 | $1,584,820 | $627,551 |
| 2019 | 817 | 5,843 | 79 | 1.51 | $1,643,580 | $608,103 |
| 2018 | 892 | 5,280 | 78 | 1.37 | $1,541,995 | $551,843 |
| 2017 | 921 | 5,171 | 78 | 1.38 | $1,448,755 | $527,314 |
| 2016 | 813 | 5,040 | 77 | 1.50 | $1,594,550 | $584,472 |
| 2015 | 609 | 3,565 | 76 | 1.54 | $1,134,640 | $436,669 |
| 2014 | 554 | 6,852 | 77 | 1.36 | $1,336,460 | $505,001 |
| 2013 | 431 | 3,384 | 76 | 1.45 | $1,064,665 | $400,082 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 40 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 164 | $161,048 | $942 |
| Return visit (30+ min) | 525 | $102,212 | $114 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 284 | $56,369 | $192 |
| Long return visit (40+ min) | 223 | $54,323 | $158 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 94 | $44,744 | $471 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $29,619 | $110 |
| New patient visit (60+ min) | 100 | $19,549 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $17,186 | $159 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 67 | $16,151 | $238 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 94 | $14,739 | $78 |
| Ultrasound of both sides of head and neck blood flow | 53 | $10,881 | $205 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 47 | $10,572 | $32 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 43 | $8,329 | $189 |
| Injection, regadenoson, 0.1 mg | 47 | $7,925 | None |
| Critical care, first 30-74 minutes | 22 | $7,897 | $188 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 14 | $7,844 | $560 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $7,565 | $63 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 101 | $6,623 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 337 | $5,982 | $14 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 52 | $4,322 | $82 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 165 | $4,036 | $23 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 32 | $4,019 | $23 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 13 | $3,735 | $287 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 18 | $3,597 | $23 |
| Ultrasound of leg arteries or artery grafts | 12 | $3,427 | $245 |
| New patient visit (45+ min) | 21 | $3,382 | $161 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 11 | $3,207 | $292 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 47 | $3,190 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 44 | $3,103 | $26 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 138 | $2,387 | $6 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 25 | $2,196 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,970 | $73 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 60 | $1,816 | $22 |
| Programming of dual lead pacemaker system | 18 | $1,677 | $76 |
| Review by radiologist of both arms or legs arteries image | 17 | $1,472 | $82 |
| Nuclear medicine study of heart muscle blood flow by pet | 52 | $1,435 | $27 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 73 | $857 | $11 |
| Ultrasonic guidance for blood vessel access | 65 | $836 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 52 | $684 | $13 |
| Injection for imaging of aorta above heart valve with review by radiologist | 11 | $352 | $32 |
2022: 39 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 164 | $166,124 | $983 |
| Return visit (30+ min) | 509 | $100,723 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 290 | $59,527 | $198 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 118 | $56,843 | $482 |
| Long return visit (40+ min) | 212 | $48,904 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $27,132 | $93 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 117 | $18,989 | $81 |
| New patient visit (60+ min) | 90 | $17,217 | $191 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $14,117 | $179 |
| Injection, regadenoson, 0.1 mg | 60 | $11,656 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 44 | $10,641 | $242 |
| Critical care, first 30-74 minutes | 21 | $9,861 | $193 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 46 | $8,947 | $25 |
| Ultrasound of both sides of head and neck blood flow | 43 | $8,921 | $207 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | $8,309 | $63 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 128 | $8,118 | $62 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 12 | $6,036 | $464 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 29 | $5,683 | $196 |
| Telephone medical discussion with physician, 21-30 minutes | 45 | $5,133 | $103 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 28 | $4,994 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 304 | $4,606 | $13 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 162 | $3,869 | $23 |
| New patient visit (45+ min) | 28 | $3,697 | $132 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 12 | $3,396 | $283 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 17 | $3,233 | $23 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $3,067 | $279 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 37 | $2,955 | $80 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 36 | $2,675 | $26 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 41 | $2,416 | $24 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 130 | $2,338 | $6 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 69 | $2,035 | $22 |
| Programming of dual lead pacemaker system | 20 | $1,942 | $81 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 17 | $1,632 | $82 |
| Nuclear medicine study of heart muscle blood flow by pet | 37 | $1,000 | $27 |
| Review by radiologist of both arms or legs arteries image | 11 | $905 | $82 |
| Injection for imaging of aorta above heart valve with review by radiologist | 16 | $711 | $44 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 51 | $604 | $11 |
| Ultrasonic guidance for blood vessel access | 48 | $589 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 36 | $477 | $13 |
2021: 38 services
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 181 | $149,841 | $793 |
| Return visit (30+ min) | 518 | $121,208 | $114 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 182 | $95,581 | $525 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 292 | $62,577 | $207 |
| Long return visit (40+ min) | 199 | $49,737 | $167 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 157 | $30,432 | $96 |
| Injection, regadenoson, 0.1 mg | 92 | $17,514 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $17,262 | $95 |
| New patient visit (60+ min) | 72 | $13,973 | $194 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $12,061 | $183 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 188 | $12,015 | $63 |
| Replacement of aortic valve through the skin and femoral artery | 16 | $10,575 | $661 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 46 | $9,848 | $26 |
| Critical care, first 30-74 minutes | 16 | $9,387 | $196 |
| Ultrasound of both sides of head and neck blood flow | 33 | $7,067 | $214 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 11 | $6,367 | $579 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 32 | $6,276 | $24 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 65 | $5,606 | $65 |
| Ultrasound of leg arteries or artery grafts | 16 | $4,902 | $272 |
| New patient visit (45+ min) | 34 | $4,834 | $142 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 263 | $4,717 | $14 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 21 | $4,678 | $223 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 183 | $4,547 | $24 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 15 | $3,974 | $265 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 13 | $3,792 | $292 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 41 | $3,766 | $28 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 17 | $3,132 | $184 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 35 | $3,066 | $27 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 14 | $2,892 | $24 |
| Programming of dual lead pacemaker system | 30 | $2,768 | $64 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,696 | $121 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 86 | $1,645 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 21 | $1,519 | $69 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 17 | $1,430 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,127 | $66 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 48 | $573 | $11 |
| Ultrasonic guidance for blood vessel access | 43 | $543 | $12 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $456 | $17 |
2020: 38 services
| Return visit (30+ min) | 487 | $93,124 | $100 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 105 | $84,487 | $790 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 155 | $76,979 | $497 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 267 | $59,772 | $208 |
| Long return visit (40+ min) | 214 | $46,011 | $133 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 155 | $30,285 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 101 | $24,088 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $16,330 | $186 |
| New patient visit (60+ min) | 74 | $13,822 | $187 |
| Injection, regadenoson, 0.1 mg | 73 | $13,737 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 47 | $11,489 | $244 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 160 | $10,334 | $63 |
| Critical care, first 30-74 minutes | 18 | $9,670 | $201 |
| Ultrasound of both sides of head and neck blood flow | 45 | $9,090 | $202 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 16 | $8,140 | $452 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 83 | $7,614 | $69 |
| Replacement of aortic valve through the skin and femoral artery | 11 | $7,392 | $672 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 31 | $5,965 | $192 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 235 | $4,750 | $16 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 14 | $4,208 | $301 |
| Ultrasound of leg arteries or artery grafts | 13 | $3,993 | $250 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 18 | $2,804 | $25 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 126 | $2,449 | $6 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 95 | $2,395 | $25 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $2,234 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 38 | $2,172 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,076 | $67 |
| New patient visit (45+ min) | 14 | $2,055 | $147 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 22 | $2,007 | $87 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 33 | $1,924 | $28 |
| Programming of dual lead pacemaker system | 22 | $1,705 | $61 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 18 | $1,614 | $85 |
| External ekg recording for more than 48 hours up to 21 days | 47 | $1,112 | $24 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 47 | $939 | $20 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 36 | $786 | $18 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 11 | $722 | $66 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 55 | $689 | $11 |
| Ultrasonic guidance for blood vessel access | 41 | $570 | $13 |
2019: 41 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 180 | $91,086 | $503 |
| Return visit (30+ min) | 554 | $80,898 | $97 |
| Long return visit (40+ min) | 268 | $62,915 | $134 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 277 | $61,133 | $207 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 151 | $35,247 | $94 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 181 | $35,025 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 116 | $22,307 | $181 |
| Injection, regadenoson, 0.1 mg | 93 | $16,973 | None |
| New patient visit (60+ min) | 89 | $16,819 | $189 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 199 | $12,658 | $63 |
| Replacement of aortic valve through the skin and femoral artery | 17 | $12,541 | $738 |
| Critical care, first 30-74 minutes | 33 | $10,935 | $199 |
| Ultrasound of both sides of head and neck blood flow | 52 | $9,677 | $183 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 16 | $9,287 | $580 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | $8,862 | $67 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 40 | $8,525 | $208 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 17 | $7,911 | $396 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 32 | $7,354 | $230 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 23 | $6,478 | $282 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 277 | $6,218 | $16 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 19 | $5,557 | $292 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 67 | $5,476 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $4,971 | $66 |
| Ultrasound of leg arteries or artery grafts | 18 | $4,538 | $252 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 178 | $3,613 | $6 |
| Programming of dual lead pacemaker system | 38 | $3,308 | $54 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 32 | $2,794 | $85 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 90 | $2,639 | $20 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,991 | $100 |
| External shock to heart to regulate heart beat | 11 | $1,640 | $103 |
| External ekg recording for more than 48 hours up to 21 days | 53 | $1,578 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 53 | $1,370 | $24 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,209 | $101 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 25 | $1,152 | $26 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 23 | $1,097 | $27 |
| Ultrasonic guidance for blood vessel access | 79 | $1,059 | $13 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 86 | $1,013 | $11 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 13 | $922 | $13 |
| Injection for imaging of aorta above heart valve with review by radiologist | 11 | $505 | $46 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $401 | $33 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $36 | $3 |
2018: 36 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 176 | $89,725 | $504 |
| Return visit (30+ min) | 621 | $82,339 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 273 | $58,319 | $205 |
| Long return visit (40+ min) | 244 | $48,082 | $127 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 177 | $33,781 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $25,371 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $21,246 | $182 |
| New patient visit (60+ min) | 107 | $19,089 | $178 |
| Injection, regadenoson, 0.1 mg | 93 | $16,492 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 192 | $12,043 | $61 |
| Ultrasound of both sides of head and neck blood flow | 53 | $11,261 | $209 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 46 | $10,819 | $235 |
| Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | 17 | $10,796 | $568 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 98 | $7,798 | $67 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 40 | $7,141 | $166 |
| Removal of plaque, insertion of stent and balloon dilation of single coronary artery or branch | 13 | $7,089 | $545 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 15 | $6,823 | $401 |
| Critical care, first 30-74 minutes | 20 | $6,271 | $196 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 74 | $6,254 | $82 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 282 | $5,630 | $16 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 19 | $5,397 | $284 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $3,726 | $65 |
| Ultrasound of leg arteries or artery grafts | 13 | $3,719 | $266 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 120 | $3,654 | $20 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 32 | $2,972 | $83 |
| Programming of dual lead pacemaker system | 42 | $2,965 | $52 |
| New patient visit (45+ min) | 22 | $2,963 | $135 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 145 | $2,575 | $6 |
| External shock to heart to regulate heart beat | 14 | $1,698 | $100 |
| Complete ultrasound study of arm and leg arteries | 12 | $1,412 | $118 |
| Ultrasonic guidance for blood vessel access | 69 | $914 | $13 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 69 | $863 | $11 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 16 | $724 | $28 |
| External ekg recording for more than 48 hours up to 21 days | 24 | $681 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 15 | $607 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 24 | $588 | $24 |
2017: 32 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 270 | $103,608 | $382 |
| Return visit (30+ min) | 591 | $80,112 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 273 | $61,331 | $219 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 199 | $37,820 | $95 |
| Long return visit (40+ min) | 198 | $31,335 | $124 |
| New patient visit (60+ min) | 121 | $21,883 | $181 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $21,467 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $20,780 | $93 |
| Injection, regadenoson, 0.1 mg | 106 | $18,253 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 209 | $14,068 | $65 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 48 | $12,854 | $268 |
| Ultrasound of both sides of head and neck blood flow | 45 | $8,944 | $194 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 36 | $7,613 | $200 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $6,867 | $65 |
| Ultrasound of leg arteries or artery grafts | 22 | $6,079 | $264 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 255 | $5,035 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 82 | $4,968 | $58 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 56 | $4,766 | $77 |
| New patient visit (45+ min) | 33 | $4,393 | $133 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 136 | $3,792 | $18 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 11 | $3,424 | $311 |
| Complete ultrasound study of arm and leg arteries | 24 | $2,926 | $117 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 129 | $2,478 | $6 |
| Programming of dual lead pacemaker system | 39 | $2,385 | $52 |
| External shock to heart to regulate heart beat | 16 | $1,913 | $101 |
| Short return visit (20+ min) | 21 | $1,384 | $66 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 14 | $1,322 | $83 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 20 | $864 | $27 |
| Ultrasonic guidance for blood vessel access | 59 | $794 | $13 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $793 | $66 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 16 | $734 | $31 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 60 | $670 | $11 |
2016: 34 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 214 | $107,851 | $499 |
| Return visit (30+ min) | 524 | $75,689 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 305 | $73,070 | $220 |
| Long return visit (40+ min) | 315 | $57,378 | $125 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 216 | $41,410 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 94 | $20,009 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $18,518 | $93 |
| Injection, regadenoson, 0.1 mg | 110 | $18,427 | None |
| New patient visit (60+ min) | 99 | $17,783 | $180 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 228 | $15,290 | $65 |
| Ultrasound of both sides of head and neck blood flow | 77 | $14,451 | $188 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 47 | $12,798 | $272 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 38 | $8,415 | $216 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $6,944 | $64 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 70 | $6,125 | $81 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 18 | $6,044 | $318 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 279 | $5,977 | $16 |
| Ultrasound of leg arteries or artery grafts | 22 | $5,166 | $191 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 78 | $4,813 | $57 |
| New patient visit (45+ min) | 32 | $4,705 | $147 |
| Critical care, first 30-74 minutes | 14 | $4,501 | $196 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 129 | $3,931 | $18 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $2,304 | $209 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 24 | $2,148 | $83 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 11 | $2,094 | $190 |
| Programming of dual lead pacemaker system | 37 | $2,061 | $48 |
| External shock to heart to regulate heart beat | 12 | $1,670 | $111 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 14 | $1,151 | $82 |
| Ultrasonic guidance for blood vessel access | 67 | $909 | $13 |
| Short return visit (20+ min) | 13 | $892 | $69 |
| Review by radiologist of both arms or legs arteries image | 13 | $733 | $56 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 16 | $702 | $29 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 46 | $618 | $6 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 16 | $537 | $32 |
2015: 27 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 155 | $77,661 | $498 |
| Return visit (30+ min) | 413 | $68,226 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 202 | $45,650 | $222 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 155 | $40,996 | $131 |
| Long return visit (40+ min) | 152 | $28,896 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $20,457 | $93 |
| New patient visit (60+ min) | 109 | $19,804 | $182 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 85 | $15,823 | $176 |
| Injection, regadenoson, 0.1 mg | 89 | $14,606 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 167 | $11,200 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $8,085 | $65 |
| Ultrasound of both sides of head and neck blood flow | 30 | $6,261 | $209 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 28 | $5,750 | $205 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 70 | $4,225 | $56 |
| New patient visit (45+ min) | 27 | $4,016 | $149 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 12 | $3,762 | $314 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $3,556 | $274 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 171 | $3,370 | $16 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 13 | $3,262 | $251 |
| Ultrasound of leg arteries or artery grafts | 15 | $3,231 | $215 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 35 | $2,660 | $74 |
| Programming of dual lead pacemaker system | 20 | $1,555 | $49 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 16 | $1,497 | $83 |
| Review by radiologist of both arms or legs arteries image | 17 | $1,010 | $56 |
| Ultrasonic guidance for blood vessel access | 32 | $491 | $13 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $373 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 11 | $356 | $24 |
2014: 32 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 196 | $97,907 | $494 |
| Return visit (30+ min) | 343 | $58,729 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 226 | $52,961 | $225 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 196 | $51,590 | $131 |
| Long return visit (40+ min) | 227 | $46,475 | $125 |
| New patient visit (60+ min) | 127 | $23,162 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 75 | $16,479 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $15,518 | $176 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 203 | $13,381 | $64 |
| Injection, regadenoson, 0.1 mg | 76 | $12,456 | None |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 45 | $10,387 | $226 |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 13 | $9,494 | $432 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $7,622 | $64 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 66 | $7,334 | None |
| Ultrasound of both sides of head and neck blood flow | 37 | $7,063 | $191 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 19 | $5,590 | $280 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 70 | $4,257 | $56 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $3,942 | $282 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 41 | $3,595 | $82 |
| Ultrasound of leg arteries or artery grafts | 14 | $3,296 | $235 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 162 | $3,273 | $16 |
| Critical care, first 30-74 minutes | 12 | $2,737 | $195 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 25 | $2,228 | $80 |
| New patient visit (45+ min) | 14 | $2,026 | $145 |
| Programming of dual lead pacemaker system | 22 | $1,681 | $47 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 20 | $1,591 | $80 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,158 | $97 |
| Hospital observation care on day of discharge | 15 | $1,109 | $65 |
| Review by radiologist of both arms or legs arteries image | 19 | $1,068 | $56 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 15 | $1,015 | $68 |
| Injection for imaging of aorta above heart valve with review by radiologist | 18 | $780 | $43 |
| Ultrasonic guidance for blood vessel access | 29 | $412 | $13 |
2013: 35 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 123 | $64,094 | $513 |
| Long return visit (40+ min) | 204 | $47,866 | $129 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 124 | $32,918 | $131 |
| Return visit (30+ min) | 198 | $32,646 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 138 | $27,438 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 82 | $25,155 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $16,038 | $174 |
| New patient visit (60+ min) | 82 | $14,708 | $179 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 38 | $9,411 | $230 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 29 | $9,238 | $308 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 126 | $8,839 | $67 |
| Injection, regadenoson, 0.1 mg | 52 | $8,778 | None |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 40 | $6,856 | None |
| Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | 11 | $6,577 | $411 |
| Ultrasound of both sides of head and neck blood flow | 32 | $5,857 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $5,137 | $63 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 55 | $4,902 | $83 |
| Critical care, first 30-74 minutes | 16 | $4,585 | $191 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 65 | $4,011 | $55 |
| Ultrasound of leg arteries or artery grafts | 14 | $3,706 | $195 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | 35 | $3,167 | $77 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 138 | $2,821 | $18 |
| Insertion of tube into chest or arm artery, each first order branch | 23 | $2,797 | $108 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 11 | $2,550 | $232 |
| Insertion of tube into chest or arm artery, initial second order branch | 16 | $2,118 | $125 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 24 | $1,852 | $77 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 76 | $1,491 | $6 |
| New patient visit (45+ min) | 12 | $1,467 | $122 |
| Programming of dual lead pacemaker system | 17 | $1,399 | $48 |
| Review by radiologist of both arms or legs arteries image | 22 | $1,251 | $54 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,235 | $95 |
| Injection for imaging of aorta above heart valve with review by radiologist | 28 | $1,175 | $42 |
| Hospital observation care on day of discharge | 15 | $1,022 | $64 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $958 | $68 |
| Ultrasound evaluation of heart blood vessel or graft with review by radiologist, each additional vessel | 11 | $806 | $62 |
Drugs they prescribed that Part D paid
$1,538,280
Pharmacies billed $1,538,280 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 6,025) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
4,589 generic and 1,436 brand-name prescriptions · $1,538,280 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 781 | $899,344 | $1,152 |
| Xarelto | 161 | $182,854 | $1,136 |
| Entresto | 106 | $107,791 | $1,017 |
| Repatha Sureclick | 131 | $93,338 | $713 |
| Multaq | 65 | $83,960 | $1,292 |
See all 52 drugs
| Eliquis | 781 | $899,344 | $1,152 |
| Xarelto | 161 | $182,854 | $1,136 |
| Entresto | 106 | $107,791 | $1,017 |
| Repatha Sureclick | 131 | $93,338 | $713 |
| Multaq | 65 | $83,960 | $1,292 |
| Farxiga | 37 | $29,640 | $801 |
| Vascepa | 34 | $23,050 | $678 |
| Jardiance | 26 | $17,663 | $679 |
| Flecainide Acetate | 235 | $10,369 | $44 |
| Brilinta | 14 | $9,835 | $703 |
| Atorvastatin | 482 | $5,657 | $12 |
| Praluent | 12 | $5,633 | $469 |
| Ezetimibe | 175 | $5,521 | $32 |
| Rosuvastatin | 331 | $5,031 | $15 |
| Metoprolol | 297 | $4,836 | $16 |
| Losartan | 316 | $3,960 | $13 |
| Dabigatran Etexilate | 13 | $3,642 | $280 |
| Amiodarone | 105 | $2,999 | $29 |
| Metoprolol | 379 | $2,918 | $8 |
| Amlodipine Besylate | 377 | $2,544 | $7 |
| Carvedilol | 240 | $2,417 | $10 |
| Lisinopril | 226 | $2,115 | $9 |
| Sotalol | 112 | $1,907 | $17 |
| Nebivolol | 14 | $1,363 | $97 |
| Clopidogrel | 93 | $1,303 | $14 |
| Furosemide | 232 | $1,225 | $5 |
| Isosorbide Mononitrate Er | 68 | $1,112 | $16 |
| Valsartan | 18 | $1,081 | $60 |
| Hydrochlorothiazide | 197 | $952 | $5 |
| Olmesartan Medoxomil | 26 | $932 | $36 |
| Clonidine | 43 | $788 | $18 |
| Diltiazem 24hr Er (Cd) | 31 | $732 | $24 |
| Ramipril | 45 | $604 | $13 |
| Simvastatin | 51 | $587 | $12 |
| Pravastatin | 42 | $586 | $14 |
| Potassium Chloride | 27 | $555 | $21 |
| Labetalol | 16 | $488 | $31 |
| Atenolol | 42 | $424 | $10 |
| Sotalol Af | 11 | $384 | $35 |
| Warfarin | 29 | $367 | $13 |
| Fenofibrate | 17 | $342 | $20 |
| Nitroglycerin | 30 | $339 | $11 |
| Enalapril Maleate | 13 | $327 | $25 |
| Lovastatin | 18 | $318 | $18 |
| Losartan-Hydrochlorothiazide | 32 | $294 | $9 |
| Valsartan-Hydrochlorothiazide | 16 | $203 | $13 |
| Spironolactone | 18 | $193 | $11 |
| Chlorthalidone | 11 | $177 | $16 |
| Benazepril | 22 | $134 | $6 |
| Lisinopril-Hydrochlorothiazide | 26 | $110 | $4 |
| Triamterene-Hydrochlorothiazid | 21 | $39 | $2 |
| Levothyroxine | 11 | $24 | $2 |
Year by year
| 2024 | 6,025 | 665 | 0% (0) | 24% | $1,538,280 |
| 2023 | 5,536 | 633 | 0% (0) | 20% | $1,284,367 |
| 2022 | 5,323 | 621 | 0% (0) | 18% | $1,095,072 |
| 2021 | 5,261 | 603 | 0% (0) | 21% | $1,035,363 |
| 2020 | 5,756 | 587 | 0% (0) | 21% | $918,873 |
| 2019 | 5,602 | 601 | 0% (0) | 18% | $803,151 |
| 2018 | 5,419 | 587 | None | 19% | $647,176 |
| 2017 | 4,707 | 557 | None | 20% | $496,627 |
| 2016 | 4,249 | 520 | None | 24% | $402,462 |
| 2015 | 2,575 | 288 | None | 24% | $188,603 |
| 2014 | 2,304 | 257 | None | 25% | $144,834 |
| 2013 | 1,552 | 193 | None | 23% | $89,303 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 52 drugs
| Eliquis | 637 | $737,487 | $1,158 |
| Xarelto | 127 | $163,890 | $1,290 |
| Entresto | 84 | $82,451 | $982 |
| Repatha Sureclick | 101 | $78,729 | $779 |
| Multaq | 23 | $34,415 | $1,496 |
| Praluent | 18 | $16,150 | $897 |
| Farxiga | 14 | $10,871 | $776 |
| Vascepa | 19 | $10,794 | $568 |
| Brilinta | 16 | $9,522 | $595 |
| Ezetimibe | 163 | $8,335 | $51 |
| Flecainide Acetate | 163 | $8,325 | $51 |
| Atorvastatin | 473 | $5,950 | $13 |
| Nexlizet | 11 | $5,563 | $506 |
| Rosuvastatin | 264 | $5,515 | $21 |
| Metoprolol | 253 | $4,873 | $19 |
| Losartan | 295 | $4,246 | $14 |
| Sotalol | 131 | $3,501 | $27 |
| Carvedilol | 240 | $3,320 | $14 |
| Lisinopril | 271 | $2,958 | $11 |
| Amlodipine Besylate | 327 | $2,859 | $9 |
| Metoprolol | 361 | $2,479 | $7 |
| Clopidogrel | 119 | $1,940 | $16 |
| Diltiazem 24hr Er (Cd) | 25 | $1,632 | $65 |
| Amiodarone | 55 | $1,585 | $29 |
| Nebivolol | 12 | $1,479 | $123 |
| Furosemide | 220 | $1,238 | $6 |
| Isosorbide Mononitrate Er | 73 | $1,207 | $17 |
| Fenofibrate | 12 | $1,177 | $98 |
| Warfarin | 46 | $1,072 | $23 |
| Hydrochlorothiazide | 176 | $843 | $5 |
| Lisinopril-Hydrochlorothiazide | 28 | $733 | $26 |
| Valsartan-Hydrochlorothiazide | 16 | $700 | $44 |
| Nitroglycerin | 34 | $693 | $20 |
| Pravastatin | 45 | $663 | $15 |
| Valsartan | 27 | $614 | $23 |
| Ramipril | 62 | $585 | $9 |
| Potassium Chloride | 24 | $581 | $24 |
| Labetalol | 24 | $570 | $24 |
| Clonidine | 46 | $554 | $12 |
| Simvastatin | 57 | $521 | $9 |
| Losartan-Hydrochlorothiazide | 23 | $419 | $18 |
| Spironolactone | 28 | $415 | $15 |
| Atenolol | 48 | $411 | $9 |
| Digoxin | 11 | $372 | $34 |
| Triamterene-Hydrochlorothiazid | 28 | $342 | $12 |
| Enalapril Maleate | 16 | $326 | $20 |
| Fenofibrate | 19 | $293 | $15 |
| Lovastatin | 14 | $191 | $14 |
| Olmesartan Medoxomil | 13 | $162 | $12 |
| Benazepril | 26 | $155 | $6 |
| Verapamil Er | 11 | $86 | $8 |
| Chlorthalidone | 14 | $2 | $0 |
2022: 51 drugs
| Eliquis | 564 | $594,101 | $1,053 |
| Xarelto | 88 | $126,257 | $1,435 |
| Ambrisentan | 13 | $71,922 | $5,532 |
| Repatha Sureclick | 88 | $62,812 | $714 |
| Entresto | 58 | $54,185 | $934 |
| Multaq | 34 | $48,394 | $1,423 |
| Flecainide Acetate | 142 | $12,499 | $88 |
| Praluent | 13 | $10,916 | $840 |
| Ezetimibe | 159 | $10,359 | $65 |
| Vascepa | 17 | $8,053 | $474 |
| Rosuvastatin | 227 | $6,962 | $31 |
| Atorvastatin | 483 | $6,625 | $14 |
| Metoprolol | 261 | $5,702 | $22 |
| Carvedilol | 248 | $3,525 | $14 |
| Amlodipine Besylate | 323 | $3,034 | $9 |
| Lisinopril | 257 | $2,435 | $9 |
| Nebivolol | 11 | $2,431 | $221 |
| Metoprolol | 335 | $2,349 | $7 |
| Losartan | 239 | $2,263 | $9 |
| Diltiazem 24hr Er (Cd) | 41 | $2,101 | $51 |
| Sotalol | 90 | $2,065 | $23 |
| Clopidogrel | 104 | $1,956 | $19 |
| Isosorbide Mononitrate Er | 68 | $1,627 | $24 |
| Verapamil Sr | 13 | $1,464 | $113 |
| Amiodarone | 56 | $1,452 | $26 |
| Sotalol Af | 22 | $1,391 | $63 |
| Fenofibrate | 14 | $1,230 | $88 |
| Furosemide | 233 | $1,213 | $5 |
| Warfarin | 69 | $1,202 | $17 |
| Fenofibrate | 25 | $1,137 | $45 |
| Labetalol | 33 | $1,062 | $32 |
| Ramipril | 75 | $1,053 | $14 |
| Hydrochlorothiazide | 202 | $1,049 | $5 |
| Potassium Chloride | 22 | $849 | $39 |
| Valsartan | 25 | $829 | $33 |
| Valsartan-Hydrochlorothiazide | 16 | $708 | $44 |
| Nitroglycerin | 50 | $663 | $13 |
| Pravastatin | 52 | $628 | $12 |
| Enalapril Maleate | 15 | $607 | $40 |
| Spironolactone | 34 | $576 | $17 |
| Simvastatin | 64 | $564 | $9 |
| Digoxin | 20 | $552 | $28 |
| Bumetanide | 13 | $515 | $40 |
| Atenolol | 54 | $505 | $9 |
| Clonidine | 32 | $413 | $13 |
| Losartan-Hydrochlorothiazide | 30 | $323 | $11 |
| Triamterene-Hydrochlorothiazid | 31 | $294 | $9 |
| Lisinopril-Hydrochlorothiazide | 18 | $279 | $15 |
| Quinapril | 11 | $266 | $24 |
| Lovastatin | 14 | $197 | $14 |
| Benazepril | 28 | $171 | $6 |
2021: 55 drugs
| Eliquis | 551 | $521,565 | $947 |
| Xarelto | 134 | $130,004 | $970 |
| Ambrisentan | 14 | $77,454 | $5,532 |
| Repatha Sureclick | 92 | $64,630 | $703 |
| Multaq | 38 | $42,245 | $1,112 |
| Entresto | 50 | $38,823 | $776 |
| Vascepa | 47 | $20,714 | $441 |
| Brilinta | 27 | $20,069 | $743 |
| Flecainide Acetate | 160 | $15,203 | $95 |
| Praluent | 12 | $8,821 | $735 |
| Atorvastatin | 483 | $7,878 | $16 |
| Rosuvastatin | 214 | $7,200 | $34 |
| Ezetimibe | 115 | $6,816 | $59 |
| Metoprolol | 262 | $6,673 | $25 |
| Bystolic | 12 | $5,332 | $444 |
| Carvedilol | 254 | $3,657 | $14 |
| Losartan | 219 | $2,931 | $13 |
| Amlodipine Besylate | 289 | $2,530 | $9 |
| Lisinopril | 256 | $2,274 | $9 |
| Diltiazem 24hr Er (Cd) | 38 | $2,200 | $58 |
| Metoprolol | 298 | $2,170 | $7 |
| Sotalol | 84 | $2,010 | $24 |
| Sotalol Af | 20 | $1,918 | $96 |
| Isosorbide Mononitrate Er | 74 | $1,849 | $25 |
| Amiodarone | 68 | $1,728 | $25 |
| Warfarin | 95 | $1,661 | $17 |
| Verapamil Sr | 13 | $1,535 | $118 |
| Furosemide | 230 | $1,345 | $6 |
| Hydrochlorothiazide | 210 | $1,187 | $6 |
| Ramipril | 78 | $1,048 | $13 |
| Clopidogrel | 68 | $1,022 | $15 |
| Fenofibrate | 20 | $1,022 | $51 |
| Labetalol | 22 | $1,008 | $46 |
| Ranolazine Er | 14 | $960 | $69 |
| Fenofibrate | 18 | $775 | $43 |
| Digoxin | 20 | $768 | $38 |
| Enalapril Maleate | 22 | $719 | $33 |
| Simvastatin | 61 | $651 | $11 |
| Irbesartan | 14 | $617 | $44 |
| Nitroglycerin | 45 | $597 | $13 |
| Pravastatin | 39 | $516 | $13 |
| Valsartan-Hydrochlorothiazide | 19 | $515 | $27 |
| Minoxidil | 11 | $506 | $46 |
| Bisoprolol | 18 | $489 | $27 |
| Atenolol | 48 | $471 | $10 |
| Quinapril | 16 | $379 | $24 |
| Spironolactone | 41 | $359 | $9 |
| Potassium Chloride | 12 | $346 | $29 |
| Clonidine | 24 | $310 | $13 |
| Benazepril | 24 | $294 | $12 |
| Chlorthalidone | 13 | $270 | $21 |
| Losartan-Hydrochlorothiazide | 24 | $257 | $11 |
| Triamterene-Hydrochlorothiazid | 20 | $237 | $12 |
| Lovastatin | 12 | $208 | $17 |
| Lisinopril-Hydrochlorothiazide | 12 | $6 | $1 |
2020: 54 drugs
| Eliquis | 550 | $423,665 | $770 |
| Xarelto | 146 | $136,380 | $934 |
| Ambrisentan | 12 | $57,381 | $4,782 |
| Repatha Sureclick | 89 | $54,667 | $614 |
| Entresto | 59 | $45,016 | $763 |
| Brilinta | 44 | $28,480 | $647 |
| Flecainide Acetate | 210 | $21,196 | $101 |
| Vascepa | 34 | $13,924 | $410 |
| Praluent | 15 | $10,826 | $722 |
| Atorvastatin | 573 | $10,064 | $18 |
| Rosuvastatin | 223 | $9,572 | $43 |
| Ezetimibe | 125 | $8,382 | $67 |
| Metoprolol | 271 | $7,891 | $29 |
| Pradaxa | 13 | $5,974 | $460 |
| Bystolic | 14 | $5,492 | $392 |
| Losartan | 227 | $3,133 | $14 |
| Sotalol Af | 38 | $2,987 | $79 |
| Carvedilol | 278 | $2,945 | $11 |
| Amlodipine Besylate | 314 | $2,636 | $8 |
| Lisinopril | 258 | $2,599 | $10 |
| Isosorbide Mononitrate Er | 106 | $2,408 | $23 |
| Metoprolol | 322 | $2,391 | $7 |
| Diltiazem 24hr Er (Cd) | 49 | $2,322 | $47 |
| Warfarin | 140 | $2,296 | $16 |
| Sotalol | 71 | $2,169 | $31 |
| Clopidogrel | 136 | $2,134 | $16 |
| Irbesartan | 19 | $1,637 | $86 |
| Amiodarone | 77 | $1,599 | $21 |
| Fenofibrate | 23 | $1,534 | $67 |
| Furosemide | 214 | $1,435 | $7 |
| Verapamil Sr | 12 | $1,403 | $117 |
| Losartan-Hydrochlorothiazide | 36 | $1,330 | $37 |
| Hydrochlorothiazide | 231 | $1,222 | $5 |
| Diltiazem 24hr Er | 29 | $1,185 | $41 |
| Enalapril Maleate | 31 | $1,136 | $37 |
| Ramipril | 65 | $1,098 | $17 |
| Pravastatin | 52 | $1,021 | $20 |
| Nitroglycerin | 47 | $754 | $16 |
| Labetalol | 24 | $712 | $30 |
| Valsartan-Hydrochlorothiazide | 29 | $655 | $23 |
| Simvastatin | 61 | $649 | $11 |
| Nifedipine Er | 11 | $635 | $58 |
| Atenolol | 61 | $619 | $10 |
| Digoxin | 24 | $619 | $26 |
| Chlorthalidone | 12 | $572 | $48 |
| Quinapril | 18 | $486 | $27 |
| Fenofibrate | 11 | $460 | $42 |
| Hydralazine | 15 | $386 | $26 |
| Lisinopril-Hydrochlorothiazide | 23 | $350 | $15 |
| Olmesartan Medoxomil | 11 | $296 | $27 |
| Spironolactone | 35 | $268 | $8 |
| Clonidine | 27 | $267 | $10 |
| Triamterene-Hydrochlorothiazid | 30 | $259 | $9 |
| Benazepril | 19 | $206 | $11 |
2019: 50 drugs
| Eliquis | 423 | $307,557 | $727 |
| Xarelto | 135 | $116,287 | $861 |
| Entresto | 72 | $42,749 | $594 |
| Brilinta | 64 | $36,083 | $564 |
| Repatha Sureclick | 43 | $24,151 | $562 |
| Flecainide Acetate | 187 | $16,108 | $86 |
| Atorvastatin | 592 | $11,842 | $20 |
| Metoprolol | 293 | $10,623 | $36 |
| Rosuvastatin | 194 | $9,921 | $51 |
| Bystolic | 18 | $5,990 | $333 |
| Ezetimibe | 98 | $5,464 | $56 |
| Prasugrel | 18 | $4,429 | $246 |
| Amiodarone | 91 | $3,656 | $40 |
| Amlodipine Besylate | 317 | $3,252 | $10 |
| Carvedilol | 245 | $2,898 | $12 |
| Metoprolol | 355 | $2,776 | $8 |
| Sotalol Af | 57 | $2,695 | $47 |
| Isosorbide Mononitrate Er | 105 | $2,650 | $25 |
| Losartan | 226 | $2,576 | $11 |
| Lisinopril | 244 | $2,528 | $10 |
| Clopidogrel | 153 | $2,423 | $16 |
| Warfarin | 145 | $2,406 | $17 |
| Diltiazem 24hr Er (Cd) | 40 | $2,301 | $58 |
| Ramipril | 80 | $1,811 | $23 |
| Enalapril Maleate | 32 | $1,692 | $53 |
| Olmesartan Medoxomil | 13 | $1,641 | $126 |
| Hydrochlorothiazide | 261 | $1,501 | $6 |
| Fenofibrate | 29 | $1,462 | $50 |
| Sotalol | 64 | $1,360 | $21 |
| Diltiazem 24hr Er | 30 | $1,331 | $44 |
| Furosemide | 152 | $1,277 | $8 |
| Pravastatin | 46 | $1,123 | $24 |
| Savaysa | 11 | $1,057 | $96 |
| Nitroglycerin | 52 | $1,016 | $20 |
| Simvastatin | 77 | $969 | $13 |
| Atenolol | 59 | $949 | $16 |
| Verapamil Sr | 11 | $946 | $86 |
| Labetalol | 20 | $943 | $47 |
| Digoxin | 29 | $786 | $27 |
| Losartan-Hydrochlorothiazide | 47 | $756 | $16 |
| Chlorthalidone | 11 | $747 | $68 |
| Nifedipine Er | 14 | $735 | $52 |
| Fenofibrate | 11 | $580 | $53 |
| Triamterene-Hydrochlorothiazid | 36 | $514 | $14 |
| Valsartan-Hydrochlorothiazide | 12 | $509 | $42 |
| Spironolactone | 48 | $472 | $10 |
| Lisinopril-Hydrochlorothiazide | 27 | $355 | $13 |
| Quinapril | 18 | $349 | $19 |
| Clonidine | 36 | $283 | $8 |
| Benazepril | 22 | $219 | $10 |
2018: 50 drugs
| Eliquis | 408 | $256,359 | $628 |
| Xarelto | 163 | $115,868 | $711 |
| Entresto | 87 | $43,090 | $495 |
| Brilinta | 62 | $41,129 | $663 |
| Repatha Sureclick | 29 | $36,216 | $1,249 |
| Flecainide Acetate | 171 | $13,623 | $80 |
| Atorvastatin | 532 | $11,736 | $22 |
| Metoprolol | 282 | $9,953 | $35 |
| Ezetimibe | 73 | $7,422 | $102 |
| Bystolic | 18 | $7,108 | $395 |
| Rosuvastatin | 141 | $5,215 | $37 |
| Prasugrel | 29 | $4,736 | $163 |
| Sotalol Af | 57 | $3,736 | $66 |
| Amlodipine Besylate | 311 | $3,526 | $11 |
| Amiodarone | 80 | $3,098 | $39 |
| Warfarin | 163 | $2,966 | $18 |
| Lisinopril | 276 | $2,691 | $10 |
| Isosorbide Mononitrate Er | 111 | $2,567 | $23 |
| Clopidogrel | 142 | $2,502 | $18 |
| Losartan | 228 | $2,488 | $11 |
| Metoprolol | 327 | $2,464 | $8 |
| Olmesartan Medoxomil | 17 | $2,435 | $143 |
| Enalapril Maleate | 33 | $2,119 | $64 |
| Carvedilol | 247 | $2,093 | $8 |
| Coumadin | 12 | $2,005 | $167 |
| Diltiazem 24hr Er (Cd) | 32 | $1,957 | $61 |
| Hydrochlorothiazide | 246 | $1,669 | $7 |
| Ramipril | 80 | $1,662 | $21 |
| Fenofibrate | 29 | $1,452 | $50 |
| Labetalol | 23 | $1,247 | $54 |
| Cartia Xt | 32 | $1,195 | $37 |
| Furosemide | 159 | $1,126 | $7 |
| Atenolol | 61 | $1,037 | $17 |
| Simvastatin | 105 | $997 | $9 |
| Pravastatin | 45 | $995 | $22 |
| Valsartan-Hydrochlorothiazide | 17 | $990 | $58 |
| Sotalol | 50 | $966 | $19 |
| Digoxin | 14 | $886 | $63 |
| Nitroglycerin | 41 | $696 | $17 |
| Fenofibrate | 17 | $630 | $37 |
| Diltiazem 24hr Er | 13 | $590 | $45 |
| Triamterene-Hydrochlorothiazid | 32 | $535 | $17 |
| Spironolactone | 60 | $504 | $8 |
| Losartan-Hydrochlorothiazide | 31 | $477 | $15 |
| Quinapril | 21 | $411 | $20 |
| Clonidine | 28 | $344 | $12 |
| Lisinopril-Hydrochlorothiazide | 28 | $292 | $10 |
| Valsartan | 11 | $216 | $20 |
| Lovastatin | 11 | $202 | $18 |
| Benazepril | 13 | $121 | $9 |
2017: 54 drugs
| Eliquis | 334 | $194,802 | $583 |
| Xarelto | 108 | $60,807 | $563 |
| Entresto | 49 | $21,604 | $441 |
| Repatha Sureclick | 17 | $19,938 | $1,173 |
| Brilinta | 39 | $19,576 | $502 |
| Pradaxa | 19 | $15,965 | $840 |
| Flecainide Acetate | 180 | $13,734 | $76 |
| Zetia | 23 | $12,109 | $526 |
| Bystolic | 39 | $11,452 | $294 |
| Atorvastatin | 531 | $11,297 | $21 |
| Metoprolol | 217 | $8,114 | $37 |
| Olmesartan Medoxomil | 21 | $7,484 | $356 |
| Rosuvastatin | 70 | $5,274 | $75 |
| Coumadin | 19 | $3,731 | $196 |
| Ezetimibe | 23 | $3,110 | $135 |
| Amlodipine Besylate | 295 | $2,931 | $10 |
| Warfarin | 176 | $2,919 | $17 |
| Sotalol Af | 51 | $2,824 | $55 |
| Clopidogrel | 137 | $2,484 | $18 |
| Metoprolol | 307 | $2,391 | $8 |
| Olmesartan-Hydrochlorothiazide | 13 | $2,186 | $168 |
| Diltiazem 24hr Er | 41 | $2,073 | $51 |
| Carvedilol | 247 | $2,033 | $8 |
| Enalapril Maleate | 29 | $2,012 | $69 |
| Isosorbide Mononitrate Er | 115 | $1,965 | $17 |
| Lisinopril | 211 | $1,816 | $9 |
| Fenofibrate | 28 | $1,799 | $64 |
| Clonidine | 13 | $1,674 | $129 |
| Losartan | 171 | $1,442 | $8 |
| Hydrochlorothiazide | 208 | $1,289 | $6 |
| Telmisartan-Hydrochlorothiazid | 11 | $1,076 | $98 |
| Sotalol | 55 | $1,075 | $20 |
| Labetalol | 16 | $1,040 | $65 |
| Cartia Xt | 40 | $986 | $25 |
| Ramipril | 44 | $959 | $22 |
| Fenofibrate | 21 | $900 | $43 |
| Simvastatin | 92 | $799 | $9 |
| Nitroglycerin | 32 | $701 | $22 |
| Potassium Chloride | 15 | $609 | $41 |
| Furosemide | 108 | $603 | $6 |
| Atenolol | 57 | $530 | $9 |
| Valsartan-Hydrochlorothiazide | 16 | $479 | $30 |
| Pravastatin | 22 | $434 | $20 |
| Triamterene-Hydrochlorothiazid | 20 | $351 | $18 |
| Losartan-Hydrochlorothiazide | 24 | $344 | $14 |
| Amiodarone | 21 | $342 | $16 |
| Quinapril | 24 | $312 | $13 |
| Clonidine | 36 | $305 | $8 |
| Fosinopril | 11 | $294 | $27 |
| Lovastatin | 20 | $282 | $14 |
| Lisinopril-Hydrochlorothiazide | 28 | $263 | $9 |
| Spironolactone | 20 | $196 | $10 |
| Benazepril | 15 | $145 | $10 |
| Valsartan | 15 | $136 | $9 |
2016: 53 drugs
| Eliquis | 303 | $134,105 | $443 |
| Xarelto | 94 | $48,698 | $518 |
| Brilinta | 54 | $24,890 | $461 |
| Zetia | 34 | $21,827 | $642 |
| Pradaxa | 28 | $17,188 | $614 |
| Crestor | 29 | $14,251 | $491 |
| Atorvastatin | 474 | $11,268 | $24 |
| Bystolic | 60 | $10,396 | $173 |
| Benicar | 19 | $9,253 | $487 |
| Vytorin | 22 | $7,816 | $355 |
| Benicar Hct | 20 | $6,688 | $334 |
| Metoprolol | 160 | $6,315 | $39 |
| Flecainide Acetate | 183 | $6,055 | $33 |
| Diovan | 14 | $3,858 | $276 |
| Clopidogrel | 129 | $2,825 | $22 |
| Clonidine | 20 | $2,647 | $132 |
| Metoprolol | 328 | $2,546 | $8 |
| Warfarin | 162 | $2,398 | $15 |
| Coumadin | 18 | $2,079 | $116 |
| Carvedilol | 218 | $1,953 | $9 |
| Fenofibrate | 29 | $1,946 | $67 |
| Amlodipine Besylate | 241 | $1,936 | $8 |
| Lisinopril | 203 | $1,854 | $9 |
| Cartia Xt | 49 | $1,606 | $33 |
| Diltiazem 24hr Er | 35 | $1,579 | $45 |
| Isosorbide Mononitrate Er | 94 | $1,579 | $17 |
| Amiodarone | 15 | $1,323 | $88 |
| Rosuvastatin | 14 | $1,320 | $94 |
| Ramipril | 69 | $1,246 | $18 |
| Labetalol | 19 | $1,051 | $55 |
| Digoxin | 16 | $1,040 | $65 |
| Hydrochlorothiazide | 156 | $1,015 | $7 |
| Losartan | 127 | $999 | $8 |
| Sotalol Af | 35 | $951 | $27 |
| Nitrostat | 28 | $891 | $32 |
| Enalapril Maleate | 23 | $854 | $37 |
| Furosemide | 132 | $814 | $6 |
| Sotalol | 32 | $596 | $19 |
| Simvastatin | 71 | $562 | $8 |
| Pravastatin | 26 | $475 | $18 |
| Atenolol | 49 | $435 | $9 |
| Clonidine | 36 | $429 | $12 |
| Irbesartan | 11 | $420 | $38 |
| Lisinopril-Hydrochlorothiazide | 23 | $419 | $18 |
| Losartan-Hydrochlorothiazide | 26 | $397 | $15 |
| Triamterene-Hydrochlorothiazid | 25 | $385 | $15 |
| Nitroglycerin | 11 | $344 | $31 |
| Spironolactone | 20 | $251 | $13 |
| Valsartan | 16 | $214 | $13 |
| Quinapril | 22 | $198 | $9 |
| Fosinopril | 14 | $197 | $14 |
| Benazepril | 15 | $171 | $11 |
| Lovastatin | 11 | $123 | $11 |
2015: 44 drugs
| Eliquis | 100 | $38,627 | $386 |
| Xarelto | 37 | $20,577 | $556 |
| Brilinta | 46 | $13,727 | $298 |
| Benicar | 24 | $10,440 | $435 |
| Pradaxa | 22 | $10,118 | $460 |
| Crestor | 15 | $6,945 | $463 |
| Metoprolol | 103 | $6,826 | $66 |
| Atorvastatin | 277 | $6,461 | $23 |
| Bystolic | 26 | $5,708 | $220 |
| Zetia | 11 | $5,279 | $480 |
| Benicar Hct | 20 | $5,277 | $264 |
| Effient | 11 | $4,171 | $379 |
| Flecainide Acetate | 109 | $3,697 | $34 |
| Warfarin | 136 | $2,054 | $15 |
| Clopidogrel | 88 | $1,634 | $19 |
| Amiodarone | 15 | $1,509 | $101 |
| Coumadin | 13 | $1,395 | $107 |
| Amlodipine Besylate | 182 | $1,219 | $7 |
| Isosorbide Mononitrate Er | 79 | $1,177 | $15 |
| Metoprolol | 219 | $1,170 | $5 |
| Carvedilol | 111 | $1,138 | $10 |
| Lisinopril | 144 | $987 | $7 |
| Diltiazem 24hr Er | 23 | $986 | $43 |
| Losartan | 77 | $673 | $9 |
| Furosemide | 115 | $644 | $6 |
| Cartia Xt | 12 | $629 | $52 |
| Valsartan-Hydrochlorothiazide | 15 | $588 | $39 |
| Enalapril Maleate | 14 | $552 | $39 |
| Sotalol Af | 22 | $530 | $24 |
| Fenofibrate | 12 | $527 | $44 |
| Ramipril | 29 | $510 | $18 |
| Simvastatin | 42 | $381 | $9 |
| Atenolol | 33 | $348 | $11 |
| Nitrostat | 22 | $328 | $15 |
| Hydrochlorothiazide | 67 | $324 | $5 |
| Lisinopril-Hydrochlorothiazide | 23 | $309 | $13 |
| Triamterene-Hydrochlorothiazid | 11 | $214 | $19 |
| Spironolactone | 25 | $188 | $8 |
| Clonidine | 19 | $171 | $9 |
| Pravastatin | 11 | $170 | $15 |
| Sotalol | 12 | $161 | $13 |
| Digox | 12 | $145 | $12 |
| Lovastatin | 11 | $140 | $13 |
| Quinapril | 14 | $115 | $8 |
2014: 38 drugs
| Eliquis | 75 | $25,154 | $335 |
| Xarelto | 60 | $23,284 | $388 |
| Effient | 20 | $6,692 | $335 |
| Pradaxa | 14 | $6,385 | $456 |
| Atorvastatin | 240 | $5,953 | $25 |
| Benicar | 14 | $5,397 | $386 |
| Metoprolol | 83 | $5,002 | $60 |
| Bystolic | 21 | $3,887 | $185 |
| Flecainide Acetate | 75 | $3,683 | $49 |
| Benicar Hct | 11 | $3,083 | $280 |
| Amiodarone | 21 | $2,186 | $104 |
| Clopidogrel | 86 | $2,064 | $24 |
| Carvedilol | 147 | $1,565 | $11 |
| Warfarin | 128 | $1,503 | $12 |
| Coumadin | 13 | $1,424 | $110 |
| Valsartan-Hydrochlorothiazide | 21 | $1,357 | $65 |
| Amlodipine Besylate | 170 | $1,339 | $8 |
| Ramipril | 28 | $1,266 | $45 |
| Lisinopril | 145 | $1,158 | $8 |
| Diltiazem 24hr Er | 19 | $1,141 | $60 |
| Metoprolol | 150 | $1,136 | $8 |
| Fenofibrate | 14 | $1,133 | $81 |
| Losartan | 74 | $954 | $13 |
| Hydrochlorothiazide | 83 | $534 | $6 |
| Furosemide | 106 | $519 | $5 |
| Isosorbide Mononitrate Er | 24 | $501 | $21 |
| Digox | 14 | $442 | $32 |
| Spironolactone | 42 | $401 | $10 |
| Atenolol | 29 | $376 | $13 |
| Nitrostat | 24 | $352 | $15 |
| Simvastatin | 47 | $346 | $7 |
| Sotalol Af | 15 | $264 | $18 |
| Lisinopril-Hydrochlorothiazide | 25 | $250 | $10 |
| Triamterene-Hydrochlorothiazid | 15 | $248 | $17 |
| Enalapril Maleate | 16 | $243 | $15 |
| Cartia Xt | 11 | $223 | $20 |
| Quinapril | 17 | $129 | $8 |
| Clonidine | 13 | $76 | $6 |
2013: 32 drugs
| Xarelto | 42 | $14,347 | $342 |
| Atorvastatin | 141 | $7,111 | $50 |
| Pradaxa | 22 | $5,758 | $262 |
| Diovan | 12 | $4,656 | $388 |
| Effient | 16 | $4,613 | $288 |
| Eliquis | 17 | $4,550 | $268 |
| Clopidogrel | 78 | $4,051 | $52 |
| Metoprolol | 42 | $3,202 | $76 |
| Bystolic | 24 | $2,918 | $122 |
| Fenofibrate | 16 | $1,969 | $123 |
| Carvedilol | 122 | $1,575 | $13 |
| Fenofibrate | 14 | $1,550 | $111 |
| Amlodipine Besylate | 106 | $1,284 | $12 |
| Warfarin | 85 | $958 | $11 |
| Flecainide Acetate | 31 | $924 | $30 |
| Metoprolol | 92 | $923 | $10 |
| Lisinopril | 99 | $878 | $9 |
| Diltiazem Er | 18 | $825 | $46 |
| Cartia Xt | 19 | $796 | $42 |
| Ramipril | 16 | $732 | $46 |
| Losartan | 36 | $674 | $19 |
| Verapamil Er | 12 | $619 | $52 |
| Simvastatin | 63 | $616 | $10 |
| Hydrochlorothiazide | 75 | $609 | $8 |
| Lisinopril-Hydrochlorothiazide | 27 | $469 | $17 |
| Sotalol | 22 | $404 | $18 |
| Furosemide | 80 | $396 | $5 |
| Enalapril Maleate | 14 | $239 | $17 |
| Atenolol | 17 | $235 | $14 |
| Amiodarone | 14 | $185 | $13 |
| Nitrostat | 18 | $176 | $10 |
| Pantoprazole | 14 | $110 | $8 |
Money from drug and device companies
$3,451 in 2025
| 2025 | 24 | 130 | None | $3,451 |
| 2024 | 24 | 114 | None | $2,690 |
| 2023 | 25 | 88 | $13 | $2,664 |
| 2022 | 22 | 80 | None | $2,408 |
| 2021 | 22 | 101 | None | $1,896 |
| 2020 | 20 | 104 | None | $2,493 |
| 2019 | 27 | 98 | None | $4,358 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Philips North America | Coronary Other | $747 | 10 payments
|
| Novartis Pharmaceuticals | Leqvio | $537 | 25 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $383 | 16 payments
|
| Pfizer | Eliquis | $270 | 15 payments
|
| Abiomed | None | $252 | 4 payments
|
| Novo Nordisk | Wegovy | $184 | 13 payments
|
See all 130 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-16 | Jardiance | $30 |
| Amgen | Meals · 2025-12-12 | Repatha | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-11 | Eliquis | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-10 | Eliquis | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-09 | Eliquis | $24 |
| Pfizer | Meals · 2025-12-05 | Eliquis | $20 |
| Esperion Therapeutics | Meals · 2025-12-05 | Nexletol | $14 |
| Abiomed | Meals · 2025-12-04 | None | $48 |
| Alnylam Pharmaceuticals | Meals · 2025-11-25 | Amvuttra | $21 |
| Philips North America | Meals · 2025-11-20 | Coronary Other | $87 |
| Pfizer | Meals · 2025-11-19 | Eliquis | $16 |
| AtriCure | Meals · 2025-11-17 | Epi-Sense Guided Coagulation System With Visitrax | $26 |
| Novo Nordisk | Meals · 2025-11-13 | Wegovy | $13 |
| Novartis Pharmaceuticals | Meals · 2025-11-11 | Leqvio | $31 |
| Abbott Laboratories | Meals · 2025-11-11 | Amplatzer Amulet | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-10 | Kerendia | $21 |
| Novartis Pharmaceuticals | Meals · 2025-11-05 | Leqvio | $141 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-04 | Eliquis | $11 |
| AGEPHA Pharma FZ | Meals · 2025-10-29 | Lodoco | $30 |
| Philips North America | Meals · 2025-10-27 | Coronary Other | $131 |
| Pfizer | Meals · 2025-10-24 | Eliquis | $16 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-23 | Kerendia | $18 |
| Biotronik | Meals · 2025-10-23 | Acticor 7 Vr-T Dx | $21 |
| Novartis Pharmaceuticals | Meals · 2025-10-21 | Leqvio | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-13 | Eliquis | $19 |
| Philips North America | Meals · 2025-10-13 | Coronary Other | $75 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-06 | Camzyos | $123 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-03 | Eliquis | $25 |
| Shockwave Medical | Meals · 2025-09-30 | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $169 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $5 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $5 |
| Novartis Pharmaceuticals | Meals · 2025-09-30 | Leqvio | $7 |
| Pfizer | Meals · 2025-09-30 | Vyndaqel | $22 |
| Pfizer | Meals · 2025-09-26 | Eliquis | $14 |
| Novo Nordisk | Meals · 2025-09-25 | Wegovy | $21 |
| Merck Sharp & Dohme | Meals · 2025-09-23 | Verquvo | $23 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Leqvio | $9 |
| Abiomed | Meals · 2025-09-11 | None | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-09 | Eliquis | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-02 | Leqvio | $9 |
| Novartis Pharmaceuticals | Meals · 2025-09-02 | Leqvio | $9 |
| Biotronik | Meals · 2025-08-28 | Amvia Edge | $15 |
| Novartis Pharmaceuticals | Meals · 2025-08-26 | Leqvio | $4 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-26 | Jardiance | $15 |
| Abiomed | Meals · 2025-08-24 | None | $120 |
| GlaxoSmithKline | Meals · 2025-08-22 | Shingrix | $20 |
| Pfizer | Meals · 2025-08-22 | Eliquis | $18 |
| Amgen | Meals · 2025-08-21 | Repatha | $10 |
| Novartis Pharmaceuticals | Meals · 2025-08-20 | Leqvio | $9 |
| Novartis Pharmaceuticals | Meals · 2025-08-20 | Leqvio | $9 |
| Novartis Pharmaceuticals | Meals · 2025-08-17 | Leqvio | $8 |
| Amgen | Meals · 2025-08-14 | Repatha | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-12 | Eliquis | $4 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-12 | Eliquis | $23 |
| Novartis Pharmaceuticals | Meals · 2025-08-12 | Leqvio | $8 |
| Novo Nordisk | Meals · 2025-08-10 | Wegovy | $21 |
| Baxter Healthcare | Meals · 2025-08-07 | Hillrom - Carnation Ambulatory Monitor | $33 |
| Novo Nordisk | Meals · 2025-08-07 | Wegovy | $22 |
| Amgen | Meals · 2025-08-07 | Repatha | $24 |
| Pfizer | Meals · 2025-08-01 | Vyndaqel | $24 |
| Abiomed | Meals · 2025-07-30 | None | $50 |
| Novartis Pharmaceuticals | Meals · 2025-07-28 | Leqvio | $7 |
| Novo Nordisk | Meals · 2025-07-26 | Wegovy | $21 |
| Pfizer | Meals · 2025-07-25 | Eliquis | $18 |
| Edwards Lifesciences | Meals · 2025-07-22 | Sapien 3 Ultra Resilia | $32 |
| Abbott Laboratories | Meals · 2025-07-15 | Cardiomems | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-10 | Eliquis | $9 |
| Novartis Pharmaceuticals | Meals · 2025-07-08 | Leqvio | $4 |
| Heartflow | Meals · 2025-07-07 | Ffrct | $31 |
| Novartis Pharmaceuticals | Meals · 2025-06-30 | Leqvio | $10 |
| Scpharmaceuticals | Meals · 2025-06-27 | Furoscix | $19 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-06-20 | Lifevest | $12 |
| Biotronik | Meals · 2025-06-19 | Biomonitor | $15 |
| Novartis Pharmaceuticals | Meals · 2025-06-10 | Leqvio | $8 |
| Merck Sharp & Dohme | Meals · 2025-06-09 | Verquvo | $26 |
| Amgen | Meals · 2025-06-07 | Repatha | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-05 | Camzyos | $31 |
| Esperion Therapeutics | Meals · 2025-05-23 | Nexletol | $17 |
| Novo Nordisk | Meals · 2025-05-22 | Wegovy | $6 |
| Novo Nordisk | Meals · 2025-05-22 | Wegovy | $6 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-19 | Lifevest | $23 |
| Pfizer | Meals · 2025-05-16 | Eliquis | $15 |
| Novartis Pharmaceuticals | Meals · 2025-05-14 | Leqvio | $9 |
| Amgen | Meals · 2025-05-13 | Repatha | $24 |
| Merck Sharp & Dohme | Meals · 2025-05-12 | Verquvo | $26 |
| Novartis Pharmaceuticals | Meals · 2025-05-09 | Leqvio | $8 |
| Pfizer | Meals · 2025-05-09 | Vyndaqel | $22 |
| Novo Nordisk | Meals · 2025-05-02 | Wegovy | $10 |
| Amgen | Meals · 2025-05-01 | Repatha | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-29 | Jardiance | $21 |
| Novo Nordisk | Meals · 2025-04-28 | Wegovy | $21 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $5 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $140 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $147 |
| Philips North America | Meals · 2025-04-26 | Coronary Other | $36 |
| Pfizer | Meals · 2025-04-25 | Eliquis | $15 |
| Philips North America | Meals · 2025-04-25 | Coronary Other | $48 |
| Novartis Pharmaceuticals | Meals · 2025-04-24 | Leqvio | $24 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-23 | Eliquis | $2 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-23 | Eliquis | $25 |
| Amgen | Meals · 2025-04-22 | Repatha | $20 |
| Esperion Therapeutics | Meals · 2025-04-21 | Nexletol | $16 |
| Boston Scientific | Meals · 2025-04-18 | Watchman Flx | $14 |
| Novartis Pharmaceuticals | Meals · 2025-04-16 | Leqvio | $3 |
| Philips North America | Meals · 2025-04-16 | Coronary Undivided | $40 |
| Philips North America | Meals · 2025-04-15 | Coronary Undivided | $40 |
| Merck Sharp & Dohme | Meals · 2025-04-14 | Verquvo | $21 |
| Novartis Pharmaceuticals | Meals · 2025-04-01 | Leqvio | $140 |
| Pfizer | Meals · 2025-03-27 | Vyndaqel | $17 |
| Abbott Laboratories | Meals · 2025-03-27 | Cardiomems | $19 |
| Amgen | Meals · 2025-03-26 | Repatha | $10 |
| Novo Nordisk | Meals · 2025-03-25 | Wegovy | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-21 | Eliquis | $26 |
| Novo Nordisk | Meals · 2025-03-18 | Wegovy | $13 |
| Pfizer | Meals · 2025-03-13 | Eliquis | $16 |
| Amgen | Meals · 2025-03-07 | Repatha | $22 |
| Biotronik | Meals · 2025-03-06 | Biomonitor | $22 |
| Novartis Pharmaceuticals | Meals · 2025-03-04 | Leqvio | $26 |
| Amgen | Meals · 2025-02-27 | Repatha | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-26 | Camzyos | $22 |
| Merck Sharp & Dohme | Meals · 2025-02-24 | Verquvo | $22 |
| Heartflow | Meals · 2025-02-18 | Ffrct | $31 |
| Pfizer | Meals · 2025-02-14 | Eliquis | $16 |
| Boston Scientific | Meals · 2025-02-11 | Watchman Flx | $19 |
| Amgen | Meals · 2025-02-07 | Repatha | $19 |
| Novartis Pharmaceuticals | Meals · 2025-02-06 | Leqvio | $8 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-05 | Jardiance | $19 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Leqvio | $8 |
| Novartis Pharmaceuticals | Meals · 2025-01-22 | Leqvio | $9 |
| Pfizer | Meals · 2025-01-03 | Eliquis | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,690
| Novartis Pharmaceuticals | Leqvio | $468 | 28 payments
|
| Abbott Laboratories | Optis | $361 | 10 payments
|
| Amgen | Repatha | $216 | 14 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $203 | 11 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $199 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $153 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $132 | 5 payments
|
| Merck Sharp & Dohme | Verquvo | $108 | 5 payments
|
| Boston Scientific | Watchman Flx | $89 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $88 | 4 payments
|
| Sanofi-Aventis U.S. | Multaq | $86 | 3 payments
|
| Pfizer | Eliquis | $83 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $80 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $67 | 3 payments
|
| Esperion Therapeutics | Nexletol | $62 | 3 payments
|
| Novo Nordisk | Rybelsus | $59 | 3 payments
|
| Philips North America | (P88) Igt Devices Fm | $51 | 1 payment
|
| Biotronik | Amvia Edge | $44 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $30 | 1 payment
|
| Regeneron Healthcare Solutions | Evkeeza | $25 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $24 | 1 payment
|
| Heartflow | Ffrct | $23 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $22 | 1 payment
|
| Kestra Medical Technology Services | Assure Wcd | $17 | 1 payment
|
2023: $2,664
| Philips Electronics North America | (9266) Elca | $318 | 7 payments
|
| Novartis Pharmaceuticals | Leqvio | $272 | 14 payments
|
| Amgen | Repatha | $257 | 11 payments
|
| Cardiovascular Systems | Diamondback Coronary | $249 | 2 payments
|
| Boston Scientific | Watchman Flx | $186 | 4 payments
|
| Inari Medical | Flowtriever Catheter, S | $151 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $132 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $127 | 5 payments
|
| Penumbra | Indigo System | $113 | 1 payment
|
| Esperion Therapeutics | Nexletol | $111 | 5 payments
|
| Biotronik | Edora 8 Dr-T | $110 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $101 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $99 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $92 | 5 payments
|
| Actelion Pharmaceuticals US | Opsumit | $54 | 2 payments
|
| Pfizer | Eliquis | $48 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $44 | 2 payments
|
| Terumo Medical | Heartrail | $40 | 2 payments
|
| Atricure | Atriclip Laa Exclusion System | $34 | 1 payment
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $32 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $31 | 2 payments
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $22 | 1 payment
|
| Medtronic | Corevalve Evolut R | $20 | 1 payment
|
| Regeneron Healthcare Solutions | Evkeeza | $14 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $7 | 1 payment
|
2022: $2,408
| Biotronik | Biomonitor | $504 | 10 payments
|
| Bard Peripheral Vascular | Lutonix Drug Coated Balloon | $224 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $176 | 10 payments
|
| Novartis Pharmaceuticals | Entresto | $175 | 12 payments
|
| Actelion Pharmaceuticals US | Opsumit | $156 | 6 payments
|
| Janssen Pharmaceuticals | Xarelto | $154 | 8 payments
|
| Abiomed | Impella | $148 | 1 payment
|
| Boston Scientific | Avvigo Guidance System | $132 | 2 payments
|
| Amgen | Repatha | $124 | 4 payments
|
| Merck Sharp & Dohme | Verquvo | $99 | 5 payments
|
| Esperion Therapeutics | Nexletol | $89 | 4 payments
|
| Alnylam Pharmaceuticals | Onpattro | $81 | 3 payments
|
| Inari Medical | Flowtriever Catheter, S | $73 | 1 payment
|
| Abbott Laboratories | Merlin@Home | $61 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $46 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $36 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $31 | 1 payment
|
| Astellas Pharma US | Lexiscan | $23 | 1 payment
|
| Cardiovascular Systems | Diamondback Peripheral | $23 | 1 payment
|
| iRhythm Technologies | Zio Xt Patch | $20 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $18 | 1 payment
|
| Pfizer | Eliquis | $15 | 1 payment
|
2021: $1,896
| Biotronik | Rivacor | $184 | 5 payments
|
| Merck Sharp & Dohme | Verquvo | $177 | 9 payments
|
| Janssen Pharmaceuticals | Xarelto | $160 | 13 payments
|
| Medtronic | Corevalve Evolut | $156 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $150 | 12 payments
|
| Actelion Pharmaceuticals US | Opsumit | $130 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $127 | 8 payments
|
| Abbott Laboratories | Mitraclip System | $125 | 8 payments
|
| Amgen | Repatha | $120 | 5 payments
|
| Amarin Pharma | Vascepa | $90 | 5 payments
|
| Boston Scientific | Watchman | $78 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $69 | 4 payments
|
| Esperion Therapeutics | Nexletol | $49 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $48 | 2 payments
|
| Kiniksa Pharmaceuticals | None | $47 | 2 payments
|
| Pfizer | Eliquis | $40 | 2 payments
|
| Philips Electronics North America | (8333) Igt D Coronary | $37 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $34 | 2 payments
|
| Kowa Pharmaceuticals America | Livalo | $25 | 1 payment
|
| HeartFlow | Ffrct | $20 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $19 | 1 payment
|
| Astellas Pharma US | Lexiscan | $12 | 1 payment
|
2020: $2,493
| Amgen | Repatha | $322 | 12 payments
|
| Amarin Pharma | Vascepa | $317 | 16 payments
|
| Biotronik | None | $230 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $194 | 11 payments
|
| Medtronic Vascular | Micra | $190 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $172 | 8 payments
|
| Shockwave Medical | Vascular Lithotripsy | $131 | 1 payment
|
| Abbott Laboratories | Confirm Rx | $130 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $124 | 6 payments
|
| Novartis Pharmaceuticals | Entresto | $117 | 10 payments
|
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $113 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $85 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $82 | 4 payments
|
| Philips Electronics North America | (7999) Src Undivided | $74 | 1 payment
|
| Esperion Therapeutics | Nexletol | $70 | 4 payments
|
| Sanofi-Aventis U.S. | Multaq | $59 | 3 payments
|
| Lundbeck | Northera | $23 | 1 payment
|
| Boston Scientific | Watchman | $22 | 1 payment
|
| Pfizer | Eliquis | $20 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $17 | 1 payment
|
2019: $4,358
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $1,039 | 8 payments
|
| Biotronik | None | $912 | 9 payments
|
| Amgen | Repatha | $264 | 10 payments
|
| Boston Scientific | General Structural Heart | $259 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $191 | 15 payments
|
| Abbott Laboratories | Cardiomems Hf System | $177 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $156 | 11 payments
|
| Philips Electronics North America | Igt Devices Und | $148 | 1 payment
|
| Medtronic USA | Infinity Oct System | $132 | 1 payment
|
| Abiomed | Impella | $125 | 1 payment
|
| Biosense Webster | Carto 3 System | $125 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $92 | 5 payments
|
| Asahi Intecc USA | Asahi Ptca Guide Wire | $88 | 1 payment
|
| Pfizer | Eliquis | $86 | 4 payments
|
| Regeneron Healthcare Solutions | Praluent | $84 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $82 | 4 payments
|
| Actelion Pharmaceuticals US | Uptravi | $82 | 5 payments
|
| Gilead Sciences | Letairis | $67 | 3 payments
|
| Akcea Therapeutics | Tegsedi | $55 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $45 | 1 payment
|
| Amarin Pharma | Vascepa | $37 | 2 payments
|
| Astellas Pharma US | Lexiscan | $24 | 1 payment
|
| Lundbeck | Northera | $23 | 1 payment
|
| Sanofi-Aventis U.S. | Praluent | $21 | 1 payment
|
| Aegerion Pharmaceuticals | Juxtapid | $17 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $16 | 1 payment
|
| Chiesi USA | Kengreal | $12 | 1 payment
|
Checkups this office reported
21 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 79.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Appropriate Treatment for Upper Respiratory Infection (URI)As Medicare defines this measure | 100% | 22 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 97%That's most of the people this applied to. | 854 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 67%That's more than half. | 584 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 3%That's few of the people this applied to. Better on this measure. | 60 |
| Breast cancer screeningEligible women who got a mammogram | 28%That's less than half. | 215 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 41%That's less than half. | 136 |
| Checked for fall riskOlder patients screened for fall risk | 15%That's few of the people this applied to. | 908 |
| Colon cancer screeningEligible adults who got a colon cancer test | 29%That's less than half. | 643 |
See the other 13 measures
| Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <= 40%)As Medicare defines this measure | 96% | 28 |
| Daily function assessedPatients whose ability to manage daily activities was assessed | 0%That's few of the people this applied to. | 64 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 12%That's few of the people this applied to. | 1,192 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 2%That's few of the people this applied to. | 117 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 55%That's more than half. Worse on this measure. | 117 |
| HIV screeningEligible patients who were screened for HIV | 11%That's few of the people this applied to. | 413 |
| Medications listed in the chartVisits where the current medication list was documented | 94%That's most of the people this applied to. | 2,917 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 550 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 927 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 4%That's few of the people this applied to. Better on this measure. | 936 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 25% | 983 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 80%That's most of the people this applied to. | 1,027 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 38%That's less than half. | 1,287 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Improved the patient portal
- Offers telehealth visits
- ONC-ACB Surveillance Attestation
- Reports cases to public health electronically
- Reports immunizations to the state registry
Professional record
- NPI
- 1497737191
- Licence
- CA A078726
- Trained
- University of Southern California Keck School of Medicine, 2000
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X); Cardiology (207RC0000X)
- Mailing address
- 2400 Samaritan Dr, Suite 200, San Jose, CA, 95124
- NPI first listed
- 2005-11-17
- NPI last updated
- 2014-06-27
This is when the NPI record was last certified, not a medical board exam.